entity

Hsp90 inhibitors

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Hsp90 inhibitors: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

12Connections

0Hypotheses

9Analyses

12Outgoing

0Incoming

0Experiments

9Debates

No AI portrait yet

Outgoing (12)

Target	Relation	Type	Str
liver toxicity	causes	phenotype	0.90
heat shock response	triggers	process	0.90
Hepatotoxicity	causes	phenotype	0.90
dose-limiting toxicity	causes	phenotype	0.90
central nervous system	causes	brain_region	0.90
MAPT	modulates	protein	0.70
hepatotoxicity	causes	phenotype	0.70
neurodegeneration	associated_with	disease	0.70
mutant protein aggregation	prevents	mechanism	0.70
tau clearance	promotes	process	0.70
tau pathology	therapeutic_target_for	mechanism	0.50
SOD1 ALS	therapeutic_target_for	disease	0.50

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (9)

Scientific analyses that reference this entity

Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.634

How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and c

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.521

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.584

Do tau aggregates represent protective responses or primary pathogenic drivers i

neurodegeneration | 2026-04-11 | 0 hypotheses

Does structural 'normalization' of APOE4 domain interactions actually improve am

neurodegeneration | 2026-04-11 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (9)

Multi-agent debates referencing this entity

While DNAJB1 enhancement showed promise, the debate raised concerns about whethe

closed · Rounds: 4 · Score: 0.73 · 2026-04-22

The debate assumed that correcting APOE4's aberrant domain interactions would re

closed · Rounds: 4 · Score: 0.43 · 2026-04-20

The debate highlighted fundamental disagreement about tau's role - whether aggre

closed · Rounds: 4 · Score: 1.00 · 2026-04-20

The authors evaluate several ALS-associated mutations in OPTN's leucine-zipper d

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

The abstract challenges the rationale for using microtubule-stabilizing drugs in

closed · Rounds: 4 · Score: 0.68 · 2026-04-15

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

closed · Rounds: 4 · Score: 0.63 · 2026-04-13

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

closed · Rounds: 4 · Score: 0.86 · 2026-04-10

The debate identified fundamental druggability challenges for these targets due

closed · Rounds: 4 · Score: 0.95 · 2026-04-09

While the abstract establishes that intercellular transmission occurs for variou

closed · Rounds: 4 · Score: 0.95 · 2026-04-09

Related Research

Hypotheses and analyses mentioning Hsp90 inhibitors in their description or question text

No additional research found

Hsp90 inhibitors

Understanding Entity Pages

Outgoing (12)

Incoming (0)

Targeting Hypotheses (0)

Mentioning Analyses (9)

Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for

How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and c

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

Do tau aggregates represent protective responses or primary pathogenic drivers i

Does structural 'normalization' of APOE4 domain interactions actually improve am

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

What determines the selectivity and efficiency of intercellular transmission pat

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

Experiments (0)

Related Papers (0)

Debates (9)

While DNAJB1 enhancement showed promise, the debate raised concerns about whethe

The debate assumed that correcting APOE4's aberrant domain interactions would re

The debate highlighted fundamental disagreement about tau's role - whether aggre

The authors evaluate several ALS-associated mutations in OPTN's leucine-zipper d

The abstract challenges the rationale for using microtubule-stabilizing drugs in

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

The debate identified fundamental druggability challenges for these targets due

While the abstract establishes that intercellular transmission occurs for variou

Related Research